Andre A. R. Teixeira
Andre A. R. Teixeira publishes mostly in Molecular Biology, Radiology, Nuclear Medicine and Imaging and Epidemiology, on topics such as Monoclonal and Polyclonal Antibodies Research, Protein purification and stability and Glycosylation and Glycoproteins Research.
- World rank
- #2,409,239 of 7,710,434 ranked researchers
- Rank in United States
- #714,208 of 1,627,098
- Works
- 53
- Citations
- 601
- Citations per work
- 11.3
What does Andre A. R. Teixeira research?
Andre A. R. Teixeira's work is mostly in Biochemistry, Genetics and Molecular Biology (28%), Medicine (27%), Immunology and Microbiology (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences2037.4%
- Everything else1935.2%
- Health Sciences1527.4%
- Medicine1527.4%
- 1Molecular Biology28% of their works
- 2Radiology, Nuclear Medicine and Imaging14% of their works
- 3Epidemiology8% of their works
- 4Surgery5% of their works
- 5Immunology5% of their works
- 6Cellular and Molecular Neuroscience5% of their works
Research topics
- Monoclonal and Polyclonal Antibodies Research
- Protein purification and stability
- Glycosylation and Glycoproteins Research
- Trypanosoma species research and implications
- vaccines and immunoinformatics approaches
- Advanced Biosensing Techniques and Applications
- Stress Responses and Cortisol
- Research on Leishmaniasis Studies
Which keywords describe Andre A. R. Teixeira's research?
The keywords of their largest research topics: Monoclonal Antibodies, Therapeutic Antibodies, Glycosylation, Antibody Engineering, Fc Receptors, Immune System, Drug Resistance and Epidemiology.
- Treatment
- Leishmaniasis
- Protein Microarrays
- High-Throughput Analysis
- Trypanosoma cruzi
- Glycans
- Protein Aggregation
- Epidemiology
- Immune System
- Antibody Engineering
- Therapeutic Antibodies
- Monoclonal Antibodies
- Glycosylation
- Fc Receptors
- Drug Resistance
- Biopharmaceuticals
- Cancer
- Chagas Disease
- Epitope Prediction
- Peptide-MHC Binding
- Brain
- Stress
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Monoclonal Antibodies282 topics
- Therapeutic Antibodies282 topics
- Glycosylation262 topics
- Antibody Engineering191 topic
- Fc Receptors191 topic
- Immune System112 topics
- Drug Resistance102 topics
- Epidemiology102 topics
- Biopharmaceuticals91 topic
- Protein Aggregation91 topic
- Cancer71 topic
- Glycans71 topic
- Chagas Disease61 topic
- Trypanosoma cruzi61 topic
- Epitope Prediction51 topic
- High-Throughput Analysis51 topic
- Peptide-MHC Binding51 topic
- Protein Microarrays51 topic
- Brain41 topic
- Leishmaniasis41 topic
- Stress41 topic
- Treatment41 topic
Where does Andre A. R. Teixeira work?
Andre A. R. Teixeira's main affiliation in the publication record is Specifica (United States), United States.
How many publications and citations does Andre A. R. Teixeira have?
OpenAlex counts 53 works and 601 citations for Andre A. R. Teixeira, an h-index of 14, ranking #2,409,239 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Andre A. R. Teixeira. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.